Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Stroke|March 30, 2017
Pharmacogenetic Associations of β1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes)Oyunbileg Magvanjav, Caitrin W McDonough, Yan Gong, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|December 25, 2018
Effects of APOC3 Heterozygous Deficiency on Plasma Lipid and Lipoprotein MetabolismGissette Reyes-Soffer, Carol Sztalryd, Richard B Horenstein, et al.
Journal of the American Heart Association|May 29, 2015
CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) studyCaitrin W McDonough, Leslie A McClure, Braxton D Mitchell, et al.
Pharmacogenetics and Genomics|February 17, 2017
Genome-wide analysis of clopidogrel active metabolite levels identifies novel variants that influence antiplatelet responseJoshua D Backman, Jeffrey R O'Connell, Keith Tanner, et al.
Science (New York, N.Y.)|December 17, 2008
A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotectionToni I Pollin, Coleen M Damcott, Haiqing Shen, et al.
Plos Medicine|June 2, 2006
Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complicationsRong-Ze Yang, Mi-Jeong Lee, Hong Hu, et al.
Journal of the American Heart Association|October 28, 2015
Oxylipid Profile of Low-Dose Aspirin Exposure: A Pharmacometabolomics StudySandrine Ellero-Simatos, Amber L Beitelshees, Joshua P Lewis, et al.
JAMA|August 27, 2009
Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapyAlan R Shuldiner, Jeffrey R O'Connell, Kevin P Bliden, et al.
Plos One|August 21, 2012
Analysis of the gut microbiota in the old order Amish and its relation to the metabolic syndromeMargaret L Zupancic, Brandi L Cantarel, Zhenqiu Liu, et al.
Pharmacogenetics and Genomics|November 1, 2012
The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel responseJoshua P Lewis, Richard B Horenstein, Kathleen Ryan, et al.
Pageof 3